US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Yarrow Bioscience, Inc.

News headline image
Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Yarrow Bioscience, Inc.
Via Business Wire
Tickers YARW
News headline image
Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering
From Yarrow Bioscience, Inc.
Via Business Wire
Tickers YARW
News headline image
Yarrow Bioscience Announces Proposed Underwritten Public Offering
From Yarrow Bioscience, Inc.
Via Business Wire
Tickers YARW
News headline image
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update
From Yarrow Bioscience, Inc.
Via Business Wire
Tickers YARW
News headline image
Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease
From Yarrow Bioscience, Inc.
Via Business Wire
News headline image
GenSci and RTW Investments Announce Strategic Partnership on Anti-TSHR Antibody GS-098 (YB-101) for Graves’ Disease and Thyroid Eye Disease, With Global Ex-China Development Being Led by Yarrow Bioscience
From Yarrow Bioscience, Inc.
Via Business Wire